Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q3 2017 · 10-Q
Revenue$0.00$0.00— vs Q3 2016 Net Income-$130.63M-$130.63MN/M vs Q3 2016 EPS Diluted-$8.15-$8.15N/M vs Q3 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
-$126,856,000
N/M
Operating Cash Flowderived-$2,237,000N/M Free Cash Flowderived-$2,237,000— ended Sep 30, 2017 · filed Nov 14, 2017 · 45 d after period end